The shareholders of SynAct Pharma AB, reg. no. 559058-4826 (the “Company”), are invited to attend the annual general meeting to be held on Thursday 11 June 2026, at 11.00 a.m. CEST, at MAQS Advokatbyrå AB’s office at Stureplan 19 in Stockholm. Registration begins at 10.30 a.m. CEST.
Right to participate in the annual general meeting
Shareholders wishing to attend the meeting in person or by proxy must,
- be registered in the Company’s share register kept by Euroclear Sweden AB as of Wednesday 3 June 2026, and
- notify their intention to attend the annual general meeting no later than Friday 5 June 2026, by mail to SynAct Pharma AB, Medicon Village, Scheelevägen 2, 223 81 Lund. Notice can also be given by e-mail to legal@synactpharma.com.
The notification shall specify the shareholder’s complete name, address, telephone number, personal identity number or company registration number and the number of shares held by the shareholder. If the shareholder intends to bring advisors to the meeting, the number (maximum two) must be notified to the Company in the same manner as set out above.
Nominee-registered shares
Shareholders whose shares are nominee-registered in the name of a bank or other nominee must, to be able to exercise their voting rights at the meeting, request the nominee to register their shares in their own name with Euroclear Sweden AB no later than as of Wednesday 3 June 2026. Accordingly, shareholders must well in advance before this date, notify their nominee of their request of such voting rights registration. Voting rights registrations requested by shareholders and received by the nominee by Friday 5 June 2026 will be taken into account in the preparation of the share register.
Proxy
If the shareholder intends to be represented by a proxy at the meeting, the proxy must bring a written power of attorney, which is dated and duly signed by the shareholder, to the meeting. The validity term of the power of attorney may not be more than five years. If the power of attorney is issued by a legal entity, an up-to-date registration certificate or equivalent document for the legal entity showing the authorized signatory shall be attached. A template power of attorney is available at the Company’s website (www.synactpharma.com) and will be sent to shareholders who request it and state their postal address or e-mail address.
The original power of attorney and, where applicable, registration certificate or equivalent document must be brought to the meeting. In order to facilitate the entrance at the meeting, a copy of the power of attorney and other authorization documents should preferably be attached to the shareholder’s notification to participate in the meeting.
Proposed agenda
- Opening of the meeting
- Election of Chairman of the meeting
- Drawing up and approval of the voting list
- Approval of the agenda
- Election of one or two adjustment officers
- Determination as to whether the meeting has been duly convened
- Presentation by the CEO
- Presentation of the annual report and auditor’s report and the consolidated financial statements and consolidated auditor’s report as well as the auditor’s statement on the compliance of the applicable guidelines for remuneration to senior executives
- Decision on:
- Adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet
- Allocations of the Company’s profit or loss according to the adopted balance sheet
- Discharging the members of the Board of Directors and the Chief Executive Officer of their liabilities
- Determination of the number of members of the Board of Directors and the number of auditors and deputy auditors
- Determination of remuneration for the Board of Directors and the auditors
- Election of the Board of Directors, the Chairman of the Board of Directors and auditors or audit firms and any deputy auditors
- Resolution on approval of remuneration report
- Resolution on instruction and charter for the Nomination Committee
- Resolution on guidelines for remuneration to senior executives
- Resolution on authorization for the Board of Directors regarding new issues.
- Closing of the meeting.